{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:18:14Z","timestamp":1793891894400,"version":"4.8.0"},"reference-count":51,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"crossref","award":["2021CXA011"],"award-info":[{"award-number":["2021CXA011"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of Fujian Province","award":["No.2020J011014"],"award-info":[{"award-number":["No.2020J011014"]}]},{"name":"Excellent Young Scholars Cultivation Project of Fujian Medical University Union Hospital","award":["2022XH034"],"award-info":[{"award-number":["2022XH034"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,2,23]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Short-course radiotherapy (SCRT) with systemic therapy has the potential to further improve the long-term efficacy in patients with locally advanced rectal cancer (LARC). To maximise the benefits of neoadjuvant therapy for improved prognosis, it is important to determine the optimal mix of chemotherapy, immunotherapy and SCRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      Fifty treatment-na\u00efve patients with operable LARC (T3\u20134 and\/or N+) will be recruited. Patients will be synchronously treated with capecitabine plus oxaliplatin (CAPOX) chemotherapy, tislelizumab and preoperative split-course hypofraction radiotherapy (SCHR) (5\u00d77 Gy) before surgery. Chemotherapy for CAPOX starts on day 1 of every 21-day cycle: on day 1, oxaliplatin 130 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      will be injected intravenously. On days 1\u201314, capecitabine 1000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      was ingested two times a day. Simultaneously, tocilizumab 200 mg will be given intravenously on the first day of every 21-day cycle. A single 7 Gy SCHR treatment (day 7 of each 21-day cycle) will be delivered five times during the seventh day of treatment. The primary endpoint will be pathological complete response. The secondary outcomes will be the 3-year disease-free survival, local recurrence rate, overall survival, sphincter-sparing surgery rate, R0 resection rate, predictive biomarkers and quality of life.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol was approved by the Ethics Committee of Xiehe Affiliated Hospital of Fujian Medical University (XAHFMU) (No. 2021YF025-01). Results from our study will be disseminated in international peer-reviewed journals. All study procedures were developed in order to assure data protection and confidentiality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05176964\">NCT05176964<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-066976","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T10:56:53Z","timestamp":1678964213000},"page":"e066976","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05176964","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9605-450X","authenticated-orcid":false,"given":"Rong","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China"},{"name":"Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors (Fujian Medical University), Fuzhou, Fujian, People's Republic of China"},{"name":"Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive,Hematological and Breast Malignancies), Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Si","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Hospital of Zhangzhou, Zhangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2184-577X","authenticated-orcid":false,"given":"Benhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China"},{"name":"Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors (Fujian Medical University), Fuzhou, Fujian, People's Republic of China"},{"name":"Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive,Hematological and Breast Malignancies), Fuzhou, Fujian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"2025121407483838000_13.3.e066976.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338"},{"key":"2025121407483838000_13.3.e066976.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"2025121407483838000_13.3.e066976.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"2025121407483838000_13.3.e066976.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040694"},{"key":"2025121407483838000_13.3.e066976.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60484-0"},{"key":"2025121407483838000_13.3.e066976.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.9597"},{"key":"2025121407483838000_13.3.e066976.7","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5506"},{"key":"2025121407483838000_13.3.e066976.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30086-4"},{"key":"2025121407483838000_13.3.e066976.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.12.028"},{"key":"2025121407483838000_13.3.e066976.10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijrobp.2017.05.048","article-title":"Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long-course chemoradiotherapy: results of a matched pair analysis","volume":"99","author":"Markovina","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121407483838000_13.3.e066976.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw062"},{"key":"2025121407483838000_13.3.e066976.12","first-page":"320","article-title":"Short-course radiotherapy in neoadjuvant treatment for rectal cancer: a systematic review and meta-analysis","volume":"17","author":"Ma","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"2025121407483838000_13.3.e066976.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.6198"},{"key":"2025121407483838000_13.3.e066976.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2025121407483838000_13.3.e066976.15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz116"},{"key":"2025121407483838000_13.3.e066976.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x"},{"key":"2025121407483838000_13.3.e066976.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258"},{"key":"2025121407483838000_13.3.e066976.18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1016709","article-title":"The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade","volume":"4","author":"Dovedi","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025121407483838000_13.3.e066976.19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/imr.12573","article-title":"Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences","volume":"280","author":"Brix","year":"2017","journal-title":"Immunol Rev"},{"key":"2025121407483838000_13.3.e066976.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824"},{"key":"2025121407483838000_13.3.e066976.21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy551"},{"key":"2025121407483838000_13.3.e066976.22","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.356"},{"key":"2025121407483838000_13.3.e066976.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025121407483838000_13.3.e066976.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7629"},{"key":"2025121407483838000_13.3.e066976.25","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199803000-00010"},{"key":"2025121407483838000_13.3.e066976.26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025121407483838000_13.3.e066976.27","doi-asserted-by":"crossref","unstructured":"Yuki S , Bando H , Tsukada Y , et al . Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. JCO 2020;38.(15_suppl) doi:10.1200\/JCO.2020.38.15_suppl.4100","DOI":"10.1200\/JCO.2020.38.15_suppl.4100"},{"key":"2025121407483838000_13.3.e066976.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.05.054","article-title":"SO-30 efficacy and safety of neoadjuvant short-course radiation followed by mfolfox-6 plus avelumab for locally-advanced rectal adenocarcinoma: averectal study","volume":"32","author":"Shamseddine","year":"2021","journal-title":"Annals of Oncology"},{"key":"2025121407483838000_13.3.e066976.29","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025121407483838000_13.3.e066976.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039900","article-title":"Chemotherapy-Based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial","volume":"10","author":"Zheng","year":"2020","journal-title":"BMJ Open"},{"key":"2025121407483838000_13.3.e066976.31","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00384-013-1717-6","article-title":"Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies","volume":"28","author":"Bae","year":"2013","journal-title":"Int J Colorectal Dis"},{"key":"2025121407483838000_13.3.e066976.32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/jjco\/hyy062","article-title":"Feasibility of split-course stereotactic ablative radiotherapy for oligometastases","volume":"48","author":"Paik","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"2025121407483838000_13.3.e066976.33","first-page":"933","article-title":"Split-Course accelerated hypofractionated radiotherapy (SCAHRT): a safe and effective option for head and neck cancer in the elderly or infirm","volume":"36","author":"Bledsoe","year":"2016","journal-title":"Anticancer Res"},{"key":"2025121407483838000_13.3.e066976.34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/JTO.0b013e3182199a7c","article-title":"Split-Course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients","volume":"6","author":"Gielda","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2025121407483838000_13.3.e066976.35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0360-3016(96)00063-6","article-title":"Once Weekly irradiation for carcinoma of the bladder","volume":"35","author":"Rostom","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121407483838000_13.3.e066976.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(97)01943-9"},{"key":"2025121407483838000_13.3.e066976.37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-8140(96)01893-2","article-title":"Hypofractionated radiotherapy for invasive bladder cancer","volume":"43","author":"Scholten","year":"1997","journal-title":"Radiother Oncol"},{"key":"2025121407483838000_13.3.e066976.38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/clon.1999.9075","article-title":"Hypofractionated radiotherapy for patients with carcinoma of the bladder","volume":"11","author":"Jose","year":"1999","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2025121407483838000_13.3.e066976.39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijrobp.2017.01.239","article-title":"Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment","volume":"98","author":"Hafeez","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121407483838000_13.3.e066976.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.10.035"},{"key":"2025121407483838000_13.3.e066976.41","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-10-696","article-title":"Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment -- case report","volume":"10","author":"Hsieh","year":"2010","journal-title":"BMC Cancer"},{"key":"2025121407483838000_13.3.e066976.42","doi-asserted-by":"publisher","DOI":"10.3171\/2017.3.JNS162532"},{"key":"2025121407483838000_13.3.e066976.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.007"},{"key":"2025121407483838000_13.3.e066976.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.07.022"},{"key":"2025121407483838000_13.3.e066976.45","doi-asserted-by":"crossref","unstructured":"Finkelstein SE , Timmerman R , McBride WH , et al . The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011;2011. doi:10.1155\/2011\/439752","DOI":"10.1155\/2011\/439752"},{"key":"2025121407483838000_13.3.e066976.46","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-014-0717-z"},{"key":"2025121407483838000_13.3.e066976.47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2824"},{"key":"2025121407483838000_13.3.e066976.48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206870"},{"key":"2025121407483838000_13.3.e066976.49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.7516"},{"key":"2025121407483838000_13.3.e066976.50","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25429"},{"key":"2025121407483838000_13.3.e066976.51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1667\/RR13731.1","article-title":"Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells","volume":"182","author":"Aryankalayil","year":"2014","journal-title":"Radiat Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-066976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:48:49Z","timestamp":1765727329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-066976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,16]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/bmjopen-2022-066976"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-066976","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}